Eli Lilly lowers guidance for 2021

In spite of its growing revenue and positive Trulicity sales, Eli Lilly has opted to lower its 2021 guidance, according to the firm's quarterly report for the first three months of the year.

Photo: Mike Blake/Reuters/Ritzau Scanpix

US pharmaceutical company Eli Lilly lowers its upper estimate for this year's income in connection with the publication of its quarterly report on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs